Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cannabinoid receptor 2 (Homo sapiens (Human)) | BDBM239075 (US9416103, JWH-073-M4) | PDB Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank antibodypedia GoogleScholar AffyNet | Purchase MCE PC cid PC sid UniChem | Article PubMed | 78 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
The University of Kansas Curated by ChEMBL | Assay Description Agonist activity at human CB2 receptor transfected in CHO cells assessed as inhibition of forskolin-stimulated adenylyl cyclase activity after 15 min... | J Med Chem 56: 4537-50 (2013) Article DOI: 10.1021/jm400268b BindingDB Entry DOI: 10.7270/Q25M68M1 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cannabinoid receptor 2 (Homo sapiens (Human)) | BDBM239075 (US9416103, JWH-073-M4) | PDB Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank antibodypedia GoogleScholar AffyNet | Purchase MCE PC cid PC sid UniChem | US Patent | 78.3 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
The Board of Trustees of the University of Arkansas; The University of Kansas US Patent | Assay Description A functional assay screen for the inhibition of adenylate cyclase (AC) activity was chosen as the subsequent assay. This screen would allow us to gai... | US Patent US9416103 (2016) BindingDB Entry DOI: 10.7270/Q2HX1BKQ | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Cannabinoid receptor 2 (Homo sapiens (Human)) | BDBM239075 (US9416103, JWH-073-M4) | PDB Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank antibodypedia GoogleScholar AffyNet | Purchase MCE PC cid PC sid UniChem | US Patent | 251 | -37.7 | n/a | n/a | n/a | n/a | n/a | n/a | 25 |
The Board of Trustees of the University of Arkansas; The University of Kansas US Patent | Assay Description Competition receptor binding was performed as previously described [Shoemaker et al., J. Pharmacol. Exp. Ther., 314:868-75]. Briefly, 50 μg of mou... | US Patent US9416103 (2016) BindingDB Entry DOI: 10.7270/Q2HX1BKQ | |||||||||||
More data for this Ligand-Target Pair |